The Financial Times has acquired a controlling stake in Endpoints News, which covers the biopharmaceutical industry, for an undisclosed price.
Endpoints has more than 163,000 subscribers and distributes content via its daily news reports and website, and at in-person and online events.
This acquisition marks a significant milestone in the FT’s expansion in the U.S., where Endpoints is based, and deepens the FT’s coverage of the dynamic biopharma sector.
“We’re thrilled to invest in Endpoints, a fast-growing business with a robust reputation for delivering quality news to audiences across the biopharma ecosystem,” said FT Group CEO John Ridding in a statement. “There is strong alignment between Endpoints and the FT in terms of mission, business model and focus on reader revenues. This acquisition also supports our ambitions to reach new audiences in innovative sectors and grow our footprint in the U.S.”
Endpoints was founded seven years ago.
